HemaSphere (May 2023)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

  • M. Offidani,
  • S. Morè,
  • M. Cavo,
  • D. Derudas,
  • F. Di Raimondo,
  • A. Cuneo,
  • L. Baldini,
  • R. Della Pepa,
  • M. Musso,
  • M. Boccadoro,
  • P. Musto,
  • A. Belotti,
  • F. Fioritoni,
  • N. Di Renzo,
  • A. Mele,
  • B. Gamberi,
  • L. De Paoli,
  • R. Zambello,
  • S. Grammatico,
  • M. Brociner,
  • F. Fazio,
  • M. T. Petrucci

DOI
https://doi.org/10.1097/01.HS9.0000936272.88286.72
Journal volume & issue
Vol. 7, no. S2
pp. 30 – 31

Abstract

Read online

No abstracts available.